nach oben

Erschienen in:

26.04.2023 | Brief report

Gastrinomas and non-functioning pancreatic endocrine tumors in multiple endocrine neoplasia syndrome type-1 (MEN-1)

verfasst von: Luigi Camera, Francesca Boccadifuoco, Roberta Modica, Luca Messerini, Antongiulio Faggiano, Valeria Romeo, Valeria Gaudieri, Annamaria Colao, Simone Maurea, Arturo Brunetti, on behalf of the European Neuroendocrine Tumor Society (ENETS) of Naples

Erschienen in: Endocrine | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Excerpt

Multiple endocrine neoplasia type-1 (MEN-1) is a rare hereditary autosomal dominant syndrome due to frameshift and non-sense mutations in the MEN-1 tumor suppressor gene localized on the long arm of chromosome 11 [1]. Also known as Wermer syndrome, it has a prevalence of 2–20/100,000 individuals who may develop multiple neoplastic lesions arising in the parathyroid (90–95%) as well as the pituitary glands (40–50%), the pancreatic islet cells (50–60%) and the duodenal wall (35–40%) [2]. …

S.S. Guo, M.P. Sawicki, Molecular and genetic mechanisms of tumorigenes in multiple endocrine neoplasia type-1. Mol. Endocrinol. 15, 1653–1664 (2001)CrossRefPubMed

G. Effraimidis, U. Knigge, M. Rossing, P. Oturai, Å.K. Rasmussen, U. Feldt-Rasmussen, Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Semin. Cancer Biol. 79, 141–162 (2022)CrossRefPubMed

R.V. Thakker, P.J. Newey, G.V. Walls et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97, 2990–3011 (2012)CrossRefPubMed

B. Niederle, A. Selberherr, D.K. Bartsch et al. Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome – an international consensus statement. Neuroendocrinology 111, 609–630 (2021)CrossRefPubMed

G.M. Doherty, Multiple endocrine neoplasia type 1: duodenopancreatic tumors. Surg. Oncol. 12, 135–143 (2003)CrossRefPubMed

M.A. Kouvaraki, S.E. Shapiro, G.J. Cote et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J. Surg. 30, 643–653 (2006)CrossRefPubMed

M. Falconi, B. Eriksson, G. Kaltsas et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103, 153–171 (2016)CrossRefPubMed

L. Camera, S. Paoletta, C. Mollica et al. Screening of pancreaticoduodenal endocrine tumours in patients with MEN 1: multidetector-row computed tomography vs. endoscopic ultrasound. Radio. Med. 116, 595–606 (2011)CrossRef

C. Barbe, A. Murat, B. Dupas et al. Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumors in multiple endocrine neoplasia type-1. Dig. Liv Dis. 44, 228–234 (2012)CrossRef

10.

I.D. Nagtegaal, R.D. Odze, D. Klimstra et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 76, 182–188 (2020)CrossRefPubMed

11.

C. Cappelli, U. Boggi, S. Mazzeo et al. Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours. Eur. Radio. 25, 751–759 (2015)CrossRef

12.

E. Belousova, G. Karmazanovsky, A. Kriger et al. Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades. Clin. Radio. 72, 150–158 (2017)CrossRef

13.

F. Salahshour, M.M. Mehrabinejad, A. Zare Dehnavi et al. Pancreatic neuroendocrine tumors (pNETs): the predictive value of MDCT characteristics in the differentiation of histopathological grades. Abdom. Radio. 45, 3155–3162 (2020)CrossRef

14.

S. Chiloiro, F. Lanza, A. Bianchi, G. et al. Pancreatic neuroendocrine tumors in MEN-1 disease: a monocentric longitudinal and prognostic study. Endocrine 60, 362–367 (2018). https://doi.org/10.1007/S12020-017-1327-0

15.

V. Ramundo, M. Del Prete, V. Marotta et al. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. Clin. Endocrinol. 80, 850–855 (2014)CrossRef

16.

A. Faggiano, R. Modica, F. Lo Calzo et al. Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors < 2 centimeters. J. Clin. Endocrinol. Metab. 105, dgz007 (2020). https://doi.org/10.1210/clinem/dgz007

17.

S. Lastoria, F. Marciello, A. Faggiano et al. Role of ⁶⁸Ga-DOTATATE PET/CT in patients with multiple nedocrine neoplasia type 1 (MEN1). Endocrine 52, 488–494 (2016). https://doi.org/10.1007/s12020-015-0702y

18.

N. Lévy-Bohbot, C. Merle, P. Goudet et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol. Clin. Biol. 28, 1075–1081 (2004)CrossRefPubMed

19.

F. Tonelli, G. Fratini, G. Nesi et al. Pancreatectomy in multiple endocrine neoplasia type-1 related gastrinomas and pancreatic endocrine neoplasia. Ann. Surg. 244, 61–70 (2006)CrossRefPubMedPubMedCentral

20.

R. Casadei, C. Ricci, G. Taffurelli et al. Is total pancreatectomy as feasible, safe, efficacious and cost-effective as pancreaticoduodenectomy? A single center, prospective, observational study. J. Gastrointest. Surg. 20, 1595–1607 (2016). https://doi.org/10.1007/s11605-016-3201-4

Titel: Gastrinomas and non-functioning pancreatic endocrine tumors in multiple endocrine neoplasia syndrome type-1 (MEN-1)
verfasst von: Luigi Camera
Francesca Boccadifuoco
Roberta Modica
Luca Messerini
Antongiulio Faggiano
Valeria Romeo
Valeria Gaudieri
Annamaria Colao
Simone Maurea
Arturo Brunetti
on behalf of the European Neuroendocrine Tumor Society (ENETS) of Naples
Publikationsdatum: 26.04.2023
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2023
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-023-03373-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Gastrinomas and non-functioning pancreatic endocrine tumors in multiple endocrine neoplasia syndrome type-1 (MEN-1)

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Effects of successful parathyroidectomy on neuropsychological and cognitive status in patients with asymptomatic primary hyperparathyroidism

Glucose-dependent inflammatory responses in obese compared to lean individuals

Treatment of osteoporosis using a selective androgen receptor modulator ostarine in an orchiectomized rat model

Increased hexosamine biosynthetic pathway flux alters cell–cell adhesion in INS-1E cells and murine islets

Consumption of health resources in older people with differentiated thyroid carcinoma: a multicenter analysis

TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin